

Medibio Signs Annual Services Agreement with Stantec Australia for ilumen™

Highlights:

- Stantec is a global engineering, design and related professional services firm employing more than 22,000 team members across 350 locations on 6 continents.
- 1,500 Stantec employees in Australia and New Zealand will have access to ilumen™ mobile and web application for a 12-month period.
- This agreement further demonstrates the market appeal of ilumen™.

Melbourne, Australia and Minneapolis, MN – 27 February 2020: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company announces that it has signed a commercial agreement with Stantec Australia to provide its corporate health product, ilumen™ to 1,500 Stantec employees in Australia and New Zealand for a 12-month period.

Stantec cares deeply about the mental and physical well-being of its people and provides various programs and resources to support and improve the mental and physical health of its workforce. Providing ilumen™ is a further demonstration of this commitment to its employees.

Kylie Ward, Stantec Human Resources Director, Asia Pacific, says “We recognise that prevention and early intervention is key to ensuring that our people maintain good mental health. ilumen™ provides a ‘snapshot’ for our employees of their mental well-being and importantly provides our organisation with de-identified data that we are able to analyse to further measure, monitor, track and implement effective programs to support our people.”

ilumen™ is a unique data-driven mental well-being program designed to aid in the evaluation and monitoring of the mental wellbeing of a workforce. ilumen™ “closes the loop” for employers to assess the impact of mental health programs that they implement in order to optimise and achieve a fully effective and productive workplace. ilumen™ provides early screening for symptoms of depression, anxiety, and stress and a ‘well-being snapshot’ that employees can use to make improvements over time.

Jennifer Solitario, Medibio Sr. VP, Corporate Health says, “We are very excited to work with the Stantec team in Australia and New Zealand. Again, Australian companies are leading the way in applying progressive solutions to help employees reach their potential which in turn delivers benefits to Stantec Australia. We are looking forward to commencing our relationship with Stantec and we hope that this is the start of a long and mutually rewarding engagement.”

The Stantec partnership aligns with Medibio’s large scale commercialisation objectives for ilumen™.

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

ASX Announcement

Medibio Limited – 27 February 2020



About Stantec Inc

Communities are fundamental. Whether around the corner or across the globe, they provide a foundation, a sense of place and belonging. That's why at Stantec, we always **design with community in mind**.

We care the communities we serve—because they're our communities too. We're designers, engineers, scientists, and project managers, innovating together at the intersection of community, creativity, and client relationships. Balancing these priorities results in projects that advance the quality of life in communities across the globe. Stantec trades on the TSX and the NYSE under the symbol STN. Visit us at stantec.com or find us on social media.

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcm Markets.com and www.asx.com.au.

Further Information:

Website: www.medibio.com.au

Medibio Investor and Media Enquiries:

Peter Taylor
NWR Communications
peter@nwrcommunications.com.au
T: +61 (0) 412 036 231